Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04685616
Title Brentuximab Vedotin in Early Stage Hodgkin Lymphoma (RADAR)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors University College, London
Indications

Hodgkin's lymphoma

Therapies

Brentuximab vedotin + Dacarbazine + Doxorubicin + Filgrastim + Vinblastine

Bleomycin + Dacarbazine + Doxorubicin + Vinblastine

Age Groups: senior | child | adult
Covered Countries


No variant requirements are available.